Stifel Financial
RLMD icon

Stifel Financial’s Relmada Therapeutics RLMD Stock Holding History

Stifel Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,784
Closed -$281K – 3407
2021
Q2 		$281K Hold
8,784
– – ﹤0.01% 2941
2021
Q1 		$309K Hold
8,784
– – ﹤0.01% 2772
2020
Q4 		$282K Hold
8,784
– – ﹤0.01% 2622
2020
Q3 		$330K Buy
+8,784
New +$339K ﹤0.01% 2334

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial's RLMD Position: Q3 2021 in Review

Stifel Financial sold out of Relmada Therapeutics (RLMD) in Q3 2021, closing a stake of 8,784 shares — an estimated $281K sold.

Stifel Financial first reported a position in RLMD in Q3 2020 and held it in 4 quarters. The position peaked at $330K in Q3 2020. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2021.

  • Stifel Financial reported no remaining Relmada Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Stifel Financial sold 8,784 Relmada Therapeutics shares in Q3 2021, an estimated $281K.
  • Stifel Financial first reported a position in Relmada Therapeutics in Q3 2020 and held it in 4 quarters.
  • Stifel Financial's Relmada Therapeutics position peaked at $330K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2021.

Based on Stifel Financial's 13F filing for Q3 2021, filed 15 Nov 2021.